Jump to content

ABNCoV2

From Wikipedia, the free encyclopedia

ABNCoV2
Vaccine description
TargetSARS-CoV-2
Vaccine typeVirus-like particles
Clinical data
Routes of
administration
Intramuscular
Identifiers
CAS Number

ABNCoV2is a cVLPCOVID-19 vaccinecandidate developed byExpres2ion Biotechnologiesand Adaptvac, outlicensed toBavarian Nordic.[2][3][4][5]

On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.[6]

References

[edit]
  1. ^"Patent Landscape Report COVID-19-related vaccines and therapeutics"(PDF).
  2. ^"Bavarian Nordic reports encouraging preclinical data for COVID-19 vaccine candidate ahead of first-in-human trial".Bavarian Nordic.8 March 2021.Retrieved13 April2021.
  3. ^Clinical trial numberNCT04839146for "Safety and Tolerability of ABNCoV2 (COUGH-1)" atClinicalTrials.gov
  4. ^"Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine".Bavarian Nordic. 23 August 2021.Retrieved24 August2021.
  5. ^Clinical trial numberNCT05077267for "ABNCoV2 Vaccine in SARS-CoV-2 Seronegative and Seropositive Adult Subjects" atClinicalTrials.gov
  6. ^Svansø VL (9 August 2021)."Foreløbige resultater: Dansk vaccine virker i første forsøg med mennesker – og den virker godt".Berlingske.dk(in Danish).Retrieved25 January2023.